Cell News and Research

RSS

BRG1 gene loss implies lack of response of cells to retinoic acid and steroids

Retinoic acid (vitamin A) and steroids are hormones found in our body that protect against oxidative stress, reduce inflammation and are involved in cellular differentiation processes. One of the characteristics of tumours is that their cells have lost the ability to differentiate; therefore these hormones have useful properties to prevent cancer. Currently, retinoic acid and steroids are being used to treat some types of leukaemia.

16 Mar 2012

Study reveals why development of HIV treatments has been difficult

A new research report appearing in the March 2012 issue of the journal Genetics shows why the development of a cure and new treatments for HIV has been so difficult. In the report, an Australian scientist explains how he used computer simulations to discover that a population starting from a single human immunodeficiency virus can evolve fast enough to escape immune defenses.

16 Mar 2012

PCP signaling restricts neural growth during regeneration, homeostasis and development

The genetic pathway that regulates the way cells align themselves relative to each other has been found to act as a "stop sign" that signals organisms when to halt cell growth, according to new research published by biologists at the Center for Regenerative and Developmental Biology in Tufts University's School of Arts and Sciences.

16 Mar 2012

Novel sensor selectively screens single molecules passing through nanopores

A novel type of sensor, based on nanometer-scale pores in a semiconductor membrane, is a step closer to practical use in applications such as analyzing the protein contents of a single cell. Researchers pioneering single-molecule nanopore sensor technology at the Technische Universit-t M-nchen (TUM) have shown its potential through a succession of experiments over the past few years.

16 Mar 2012

CCN1 protein orchestrates cellular antiviral response in the extracellular matrix

Brain-tumor cells that are infected with a cancer-killing virus release a protein "alarm bell" that warns other tumor cells of the impending infection and enables them to mount a defense against the virus, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

16 Mar 2012

Rapid increase in number of HPV-related oral cancers in the UK

The number of oral cancer cases diagnosed each year in the UK has risen above 6,000 for the first time, new figures from Cancer Research UK show today.

16 Mar 2012

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine.

16 Mar 2012

CYFRA reliable marker for response to chemotherapy for NSCLC

Researchers found that CYFRA and change in levels of CYFRA were found to be reliable markers for response to chemotherapy for non-small cell lung cancer (NSCLC) in a study of 88 patients. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that this marker can be used to determine whether or not a patient should continue a particular chemotherapy regimen.

16 Mar 2012

Addition of inflammatory biomarkers to clinical variables improve mortality prediction in COPD

The addition of changes in inflammatory biomarkers to established clinical variables improves the prediction of mortality in patients with chronic obstructive pulmonary disease (COPD), according to a new study.

16 Mar 2012

New FSU technology could decrease the cost of drug discovery

New technology being developed at Florida State University could significantly decrease the cost of drug discovery, potentially leading to increased access to high-quality health care and cancer patients receiving personalized chemotherapy treatments.

16 Mar 2012

Kyolic AGE may reduce duration of cold and flu symptoms by 61%

Americans looking to impact their cold and flu symptoms this season may have a new weapon at their disposal. A randomized, double-blind, placebo-controlled study just published by the University of Florida determined that Kyolic Aged Garlic Extract (AGE) may reduce the duration of symptoms associated with common colds or flus by as much as 61 percent.

16 Mar 2012

Two awards to advance pancreatic cancer research

The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Stephanie K. Dougan, Ph.D., postdoctoral fellow at the Whitehead Institute for Biomedical Research, and Oliver G. McDonald, M.D., Ph.D., postdoctoral fellow at Johns Hopkins University, the 2012 Pancreatic Cancer Action Network-AACR Pathway to Leadership Grants.

16 Mar 2012

$Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy$

Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy

Medtronic, Inc. today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation (DBS) Therapy for refractory epilepsy patients.

From Medtronic 16 Mar 2012

GABA neurons could help restore muscle coordination deficits of Huntington's

Huntington's disease, the debilitating congenital neurological disorder that progressively robs patients of muscle coordination and cognitive ability, is a condition without effective treatment, a slow death sentence. But if researchers can build on new research reported this week in the journal Cell Stem Cell, a special type of brain cell forged from stem cells could help restore the muscle coordination deficits that cause the uncontrollable spasms characteristic of the disease.

16 Mar 2012

OHRI, uOttawa to lead first stem cell therapy trial for septic shock

A team of researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) has been awarded $367,000 from the Canadian Institutes of Health Research (CIHR) and $75,000 from the Stem Cell Network to lead the first clinical trial in the world of a stem cell therapy for septic shock.

16 Mar 2012

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa.

16 Mar 2012

Exposure to radiation from cell phones during pregnancy affects brain development of offspring

Exposure to radiation from cell phones during pregnancy affects the brain development of offspring, potentially leading to hyperactivity, Yale School of Medicine researchers have determined.

16 Mar 2012

New technique can sensitize cancer cells to radiation

Researchers at Winship Cancer Institute are developing a technique to remove cancer cells' defenses against radiation.

16 Mar 2012

Shire enters agreement to acquire FerroKin BioSciences

Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.

15 Mar 2012

CUMC scientists develop a way to recreate personalized immune mouse

Columbia University Medical Center (CUMC) scientists have developed a way to recreate an individual's immune system in a mouse. The "personalized immune mouse" offers researchers an unprecedented tool for individualized analysis of abnormalities that contribute to type 1 diabetes and other autoimmune diseases, starting at the onset of disease.

15 Mar 2012